India’s Obesity Burden: Urgent Health and Economic Wake-Up Call

CURRENT AFFAIRS: Obesity in India 2024, World Heart Federation Report, GLP-1 Obesity Drugs, Eli Lilly Mounjaro, Wegovy India Launch, Childhood Obesity India, Obesity-Linked Economic Cost

India’s Obesity Burden: Urgent Health and Economic Wake-Up Call

Rapid Rise of Obesity in India

India’s Obesity Burden: Urgent Health and Economic Wake-Up Call: India is facing a growing obesity crisis, mirroring global trends. According to a recent World Heart Federation report, adult obesity has quadrupled worldwide since 1990. In India, the number of obese adult women has crossed 44 million, while around 26 million men are classified as obese. This gender gap highlights a major public health concern. Childhood obesity is also on the rise, affecting 5.2 million girls and 7.3 million boys across the country.

Health Risks and Long-Term Effects

Obesity is strongly associated with increased risks of cardiovascular diseases, especially when it begins in childhood. Children with elevated Body Mass Index (BMI) are 40% more likely to suffer from heart conditions later in life. Early obesity reduces life expectancy and significantly adds to the national disease burden, requiring long-term policy and healthcare attention.

Barriers to Treatment and Awareness

Although obesity is now recognised as a disease, access to proper treatment remains inadequate. Many patients face financial and systemic barriers, including social stigma that prevents them from seeking medical help. While lifestyle changes like diet and exercise are promoted, they often fall short without continuous support. Advanced drug therapies such as GLP-1 agonists exist but are typically too expensive for the average Indian household.

Drug Innovation and Market Dynamics

The recent approval of new obesity drugs is creating optimism among healthcare providers. For instance, Eli Lilly’s Mounjaro has seen a sharp rise in global sales, while Novo Nordisk’s Wegovy is expected to enter the Indian market soon. Experts believe these products may drive the emergence of lower-cost generic alternatives, thereby widening treatment access. The weight-loss drug industry is rapidly expanding, signaling both hope and financial opportunity.

Mounting Economic Costs

Obesity is not only a health issue but also an economic burden. A study estimated that in 2019, obesity cost India $28.95 billion, and if unchecked, this number could rise to $838.6 billion by 2060. This includes healthcare expenses, loss of productivity, and long-term disability impacts. The economic projections demand immediate and sustained public health action.

The Way Forward: Inclusive Public Health Policies

To combat this epidemic, India needs comprehensive and cost-effective public health interventions. Raising public awareness, improving access to care, and supporting equitable treatment options must be prioritized. Recognising obesity as a multifactorial disease—influenced by genetics, environment, and lifestyle—will help shape more effective policies. Ensuring affordability and availability of treatments, especially in rural and underserved areas, is vital for long-term success.

STATIC GK SNAPSHOT

Category Key Data/Information
Adult Obese Women (2024) 44 million (10% of women over 20)
Adult Obese Men (2024) 26 million (5%)
Childhood Obesity (India) 5.2 million girls, 7.3 million boys
Health Risk 40% higher chance of cardiovascular issues (high BMI)
Cost of Obesity in 2019 $28.95 billion
Projected Cost by 2060 $838.6 billion
New Obesity Drug (GLP-1) Mounjaro by Eli Lilly
Upcoming Drug Wegovy by Novo Nordisk
Treatment Challenge High cost, limited access, stigma
Public Health Focus Awareness, access, affordability, sustainable policy
India’s Obesity Burden: Urgent Health and Economic Wake-Up Call
  1. India has over 44 million obese adult women in 2024, accounting for 10% of women over 20.
  2. The number of obese adult men in India reached 26 million in 2024.
  3. Childhood obesity affects 5.2 million girls and 7.3 million boys across India.
  4. According to the World Heart Federation, global adult obesity has quadrupled since 1990.
  5. Obese children with high BMI have a 40% greater risk of developing cardiovascular diseases later in life.
  6. Obesity is now recognised as a disease, but treatment access remains limited in India.
  7. Financial barriers and social stigma prevent many Indians from seeking obesity treatment.
  8. Lifestyle changes like diet and exercise are not always effective without sustained support.
  9. GLP-1 obesity drugs are emerging as promising therapies but are often too expensive.
  10. Mounjaro, a GLP-1 drug by Eli Lilly, has seen rapid global sales growth.
  11. Novo Nordisk’s Wegovy is expected to launch in India soon, expanding treatment options.
  12. Experts hope new drugs will lead to affordable generic alternatives in the obesity market.
  13. The weight-loss drug industry is growing rapidly, offering both hope and economic opportunity.
  14. In 2019, obesity cost India an estimated $28.95 billion.
  15. By 2060, obesity-related costs in India may reach $838.6 billion.
  16. These costs include healthcare expenses, productivity losses, and long-term disability impacts.
  17. Obesity’s financial burden calls for urgent public health policies.
  18. India needs inclusive, affordable, and accessible obesity treatment strategies.
  19. Obesity is influenced by genetics, lifestyle, and environment, requiring multi-pronged policies.
  20. Raising awareness and improving access to rural healthcare are key to fighting the obesity epidemic.

Q1. According to the 2024 data, how many adult women in India are classified as obese?


Q2. What is the estimated economic cost of obesity in India projected for the year 2060?


Q3. What is the name of the obesity drug by Eli Lilly mentioned in the report?


Q4. What percentage higher is the risk of cardiovascular disease in children with high BMI?


Q5. How many boys in India are affected by childhood obesity, as per recent estimates?


Your Score: 0

Daily Current Affairs May 21

Descriptive CA PDF

One-Liner CA PDF

MCQ CA PDF​

CA PDF Tamil

Descriptive CA PDF Tamil

One-Liner CA PDF Tamil

MCQ CA PDF Tamil

CA PDF Hindi

Descriptive CA PDF Hindi

One-Liner CA PDF Hindi

MCQ CA PDF Hindi

News of the Day

Premium

National Tribal Health Conclave 2025: Advancing Inclusive Healthcare for Tribal India
New Client Special Offer

20% Off

Aenean leo ligulaconsequat vitae, eleifend acer neque sed ipsum. Nam quam nunc, blandit vel, tempus.